A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01235962
Recruitment Status : Active, not recruiting
First Posted : November 8, 2010
Last Update Posted : March 30, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : October 15, 2015
  Estimated Study Completion Date : April 15, 2019
  Certification/Extension First Submitted : January 26, 2017